Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

322
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
322
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

631
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
631
Drug Therapy01:28

Drug Therapy

156
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
156
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

1.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Schizophrenia01:17

Schizophrenia

513
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
513

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological insights into schizophrenia from ancestrally diverse populations.

Nature·2026
Same author

Latent class analysis of symptoms across schizophrenia, schizoaffective disorder, and bipolar I disorder.

medRxiv : the preprint server for health sciences·2025
Same author

Insomnia and cardiovascular disease risk in schizophrenia.

Schizophrenia research·2024
Same author

Longitudinal study of insomnia, suicidal ideation, and psychopathology in schizophrenia.

Schizophrenia research·2024
Same author

Longitudinal study of inflammation and relapse in schizophrenia.

Schizophrenia research·2023
Same author

The Future of Endowed Chairs in Academic Medicine.

Academic medicine : journal of the Association of American Medical Colleges·2022
Same journal

Anabolic Androgenic Steroids: Emerging Use Disorder, Mechanisms of Action, and Clinical Considerations for Pharmacotherapy.

Focus (American Psychiatric Publishing)·2026
Same journal

Major Depression and Antidepressant Treatment: Impact on Pregnancy and Neonatal Outcomes.

Focus (American Psychiatric Publishing)·2026
Same journal

Violence Risk Factors in Psychiatric Populations.

Focus (American Psychiatric Publishing)·2026
Same journal

Contextualizing Violence Risk Associated With Hallucinogens.

Focus (American Psychiatric Publishing)·2026
Same journal

Ethical and Legal Aspects of Forensic Psychiatry.

Focus (American Psychiatric Publishing)·2026
Same journal

From Fear to Framework: Toward Understanding of Violence and Mental Illness.

Focus (American Psychiatric Publishing)·2026
See all related articles

Related Experiment Video

Updated: Nov 25, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.3K

Treatment-Resistant Schizophrenia.

Peter F Buckley1

  • 1McGlothlin Medical Education Center, Virginia Commonwealth University School of Medicine, Richmond.

Focus (American Psychiatric Publishing)
|December 21, 2020
PubMed
Summary
This summary is machine-generated.

Treatment-resistant schizophrenia (TRS) affects many patients with chronic schizophrenia who do not respond well to treatments. This article reviews current definitions and updated guidelines for managing TRS patients.

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.8K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.2K

Related Experiment Videos

Last Updated: Nov 25, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.3K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.8K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.2K

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Schizophrenia treatment research increasingly targets early-stage patients.
  • A significant number of patients with chronic schizophrenia exhibit suboptimal treatment responses.
  • This persistent symptomology defines treatment-resistant schizophrenia (TRS).

Purpose of the Study:

  • To address contemporary definitions of treatment-resistant schizophrenia (TRS).
  • To present updated clinical guidelines for managing patients with TRS.

Main Methods:

  • Review of current literature on schizophrenia treatment.
  • Analysis of recent clinical practice guidelines.

Main Results:

  • Established definitions for treatment-resistant schizophrenia (TRS).
  • Summarized updated therapeutic strategies and management protocols for TRS.

Conclusions:

  • Despite advances, effective management of TRS remains a clinical challenge.
  • Updated guidelines offer a framework for optimizing care in patients with persistent schizophrenia symptoms.